Log In
BCIQ
Print this Print this
 

IGN786

  Manage Alerts
Collapse Summary General Information
Company Igenica Inc.
DescriptionAnti-surface antigen in leukemia (SAIL) antibody-drug conjugate
Molecular Target Surface antigen in leukemia (SAIL)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard IndicationChronic lymphocytic leukemia (CLL)
Indication DetailsTreat chronic lymphocytic leukemia (CLL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/28/2015

Undisclosed

0

Undisclosed

Get a free BioCentury trial today